Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is the equivalent of a Pfizer earnings release being titled "Caduet sales fall 25%"
Just as a guess, I think they gather offline dressed in loincloths and sit around a fire getting in touch with their inner caveman. I think there's also a high proportion of Promise Keepers and Full Quiver members on that board.
I think you just caused my first case of erectile dysfunction.
Ah, but it doesn't matter to the FDA whether there are good data or not. Logically the potential exists.
An example: look at the malignancy warnings in every single TNF-alpha blocker label. No good data exist there either.
I would give the RPRX "news" from Reuters an 8 for gross stupidity and a 0 for maliciousness. I mean, come on, it would have taken all of 15 additional seconds to be accurate.
I'm going to have to think about that. Reducing levels of DHT can lead to man-boobs and erectile dysfunction, which I've heard are both kind of a bummer.
I say "man-boobs" 'cause I can't spell gynecomastica or whatever right now.
No conspiracy...just inaccurate news reporting. Standard fare in the Fox News era.
>As for the unmasking prostate part, it only normalizes T. (as you know).<
I know. But fact is testosterone levels decline naturally as men age. So raising testosterone levels to a physiologic "normal" of a 30-year-old man in a 70-year-old does have the potential to unmask prostate cancer. I don't think there's any doubt about that.
I suspect that the label will contain a black box to this effect and a recommendation to monitor PSA at 6-month intervals.
I should note, however, that there is probably less potential for Androxal to unmask PC as it's not possible to attain supraphysiologic plasma levels with Androxal.
RPRX
I posted this on the RPRX board too, but for those of you who don't read it....
This is funny. I've pasted below the Reuters report on the recent news that appeared in my E*Trade account. Now, if you read this and didn't know better (a category under which the majority of retail falls) wouldn't you think this was bad news? Especially the headline.
Might be a brief selloff tomorrow morning before the real news sinks in, depending on how many people read only this.
Whoever writes biotech news at Reuters should be shot. Or do they have a computer program writing this kind of stuff? I know they do for earnings releases.
Repros to revise testosterone drug trial design
Reuters - October 15, 2007 8:25 PM ET
NEW YORK, Oct 15 (Reuters) - Repros Therapeutics Inc (RPRX) said on Monday it plans to submit a revised protocol for future clinical trials of its experimental drug Androxal to treat testosterone deficiency, following discussions with U.S. health regulators.
"We believe Androxal may have the potential to reach a broader spectrum of endocrinological dysfunctions beyond the effects of low testosterone alone," said Chief Executive Joseph Podolski. (Reporting by Martinne Geller)
This is funny. I've pasted below the Reuters report on the recent news that appeared in my E*Trade account. Now, if you read this and didn't know better (a category under which the majority of retail falls) wouldn't you think this was bad news? Especially the headline.
Might be a brief selloff tomorrow morning before the real news sinks in, depending on how many people read only this.
Whoever writes biotech news at Reuters should be shot. Or do they have a computer program writing this kind of stuff? I know they do for earnings releases.
Repros to revise testosterone drug trial design
Reuters - October 15, 2007 8:25 PM ET
NEW YORK, Oct 15 (Reuters) - Repros Therapeutics Inc (RPRX) said on Monday it plans to submit a revised protocol for future clinical trials of its experimental drug Androxal to treat testosterone deficiency, following discussions with U.S. health regulators.
"We believe Androxal may have the potential to reach a broader spectrum of endocrinological dysfunctions beyond the effects of low testosterone alone," said Chief Executive Joseph Podolski. (Reporting by Martinne Geller)
RPRX
In case anyone was wondering, this is a big fat score for Repros. There is no doubt in anyone's mind that this drug is effective in raising testosterone...the P value for the last trial had a bunch o'zeros after the dot.
This makes Androxal an eminently partnerable product. Or an outright sale of the entire program could be in the cards.
I'm rarely this enthusiastic, but fact is this drug works and it works well. I don't think there are any significant safety concerns either, at least compared with testosterone gels--by all accounts it should be safer. Of course, there is always the concern about unmasking prostate cancer, but that concern will exist for any product modifying testosterone levels.
Canada won't introduce test for takeovers this year
Excellent news. Start buying Canroys!
TORONTO, Oct 15 (Reuters) - Canada will not introduce a national security test for foreign takeovers of Canadian firms until next year, the Minister of Finance Jim Flaherty said on Monday.
"The idea is to have something in the new year on the national security issue. Not this year," Flaherty told Reuters in an interview.
The Conservative-led government is working on legislation that would allow it to block investments by state-owned or state-controlled firms on national security grounds.
It has said the new rules would not apply to deals in progress, such as state-controlled Abu Dhabi National Energy Co's (TAQA.AD: Quote, Profile, Research) proposed C$5 billion ($5.2 billion) takeover of oil and gas producer, PrimeWest Energy Trust (PWI_u.TO: Quote, Profile, Research).
Separately, Minister of Industry Jim Prentice said he wants the national security test in place before June 2008, when a panel reviewing Canada's competition policy is due to issue a report.
"The real question is issues of transparency, governance, and ... adherence to market principles," Prentice told reporters.
"Canada is open to foreign investment through the Investment Canada Act. We want to ensure that the Investment Canada Act in no way becomes a vehicle for protectionism."
And what about all of the programs they picked up when they purchased Tanox? Or as I used to call it when I owned it: TANX.
Stelmach promises security for Alberta oil companies
Promises 'stability' for oilpatch companies
Friday, October 12, 2007
CALGARY - Alberta Premier Ed Stelmach has indicated he may be willing to give in to intense oil-industry pressure and not adopt the most contentious measures of a report that urges punishing increases in oil and gas taxes and royalties.
In a private address yesterday to about 100 executives organized by the Harvard Business School Club in Calgary, Mr. Stelmach said he "will not trounce existing agreements."
"That would destroy international confidence. That would be the wrong message to the world. I am not ready to give you the full answer on what we will decide on the royalty review, but this is in my heart," he said, according to notes taken by sources at the breakfast presentation.
The Premier's office said he is scheduled to make a formal announcement on Oct. 24 about the direction his government will take on the explosive issue.
Mr. Stelmach also told the meeting he is open to the idea of taking more time to study royalty changes if it means a better result, even though he is feeling pressured to make a decision as quickly as possible so oil companies can get on with their plans.
So far, the Premier has remained silent since the report came out on Sept. 18, even as oil companies and investors expressed outrage and threatened to pull billions of dollars out of Alberta and in effect unravel the province's energy boom.
"I am feeling better today," said one executive who attended the breakfast meeting. "The main thing you don't know is whether all this information is getting to the guy who is finally going to make the decision. And now I think that he does understand the complexities of the issue."
Mr. Stelmach told the meeting he wants to ensure "fairness" to companies, "stability" and "predictability."
Another executive said the Premier's tone left him with the impression the government would not adopt the full scope of recommendations in the Our Fair Share report.
Tom Olsen, a spokesman for Mr. Stelmach, said the Premier "is not disputing anything" said at the breakfast meeting.
But he said, "It was not the Premier's intent, in case there is a misunderstanding, to make any pronouncements on any of the recommendations. He is not going to let news of his decisions trickle out in this fashion. There will be a full and formal response."
Mr. Olsen said the Premier has heard a lot of negative feedback about the panel's proposals to rip up existing oilsands agreements.
A special panel appointed by Mr. Stelmach in February said Albertans are not getting their fair share of oil and gas revenue and proposed new levies to recoup $2-billion more annually, representing a 20% increase in the government take, even though the government is already racking up huge budget surpluses due to oil revenue and is debt free.
The proposed measures are regarded by the industry as so draconian they are already affecting company plans. Yesterday, Suncor Energy Inc., the largest oilsands company, confirmed it has held meetings with staff to announce it has halted any hirings because of the uncertainty. The company was one of the sector's most aggressive recruiters, hiring 1,000 people a year for the past five years. So far this year, Suncor has hired 960 people; its target was more than 1,200.
"We're looking at the overall business environment and there are a lot of uncertainties and cost pressures," said Suncor spokeswoman Darcie Park. "We expect [the hiring freeze] to last until the end of the year, but we'll make decisions on that as we go along."
She would not say if the recruiting pause would affect the company's multibillion-dollar expansion plans.
The panel's recommendation to rip up royalty agreements is among the most contentious.
Suncor and Syncrude Canada Ltd., a consortium of oil companies, have Crown agreements lasting until 2015.
But the panel, headed by former forestry executive Bill Hunter, recommended against grandfathering, so that changes would apply equally to all participants at the same time, even if such a move could result in legal action.
Dax Sanders, spokesman for the Harvard Business School Club, would not provide details on specific comments made by the Premier.
"We really enjoyed having the Premier speak to us about the future of Alberta," he said.
Caduet is a combination of a lipid-lowering medication (Lipitor) and an antihypertensive (Norvasc). The other amlodipine combos are with other antihypertensive drugs.
While Caduet makes theoretical sense, doctors have a hell of a lot of trouble identifying appropriate patient types and titrating the medication so that both lipids and blood pressure are within parameters. If you look at the Caduet label, there are 11 different dosages for Caduet. The only place Caduet makes sense to physicians is as a replacement for patients who are already taking both drugs.
On the other hand, the other amlodipine combinations (Exforge, for example) only treat blood pressure.
Let's just say that my suggestions were not so good
Pfizer usually has a contest to see who can name the drug. I participated in the naming of atorvastatin + amlodipine, although my admittedly crappy suggestions didn't win.
The winner, of course, was Caduet (CAD = coronary artery disease; duet = the combo of atorvastatin and amlodipine). Brilliant name, not so brilliant product.
HEB
They didn't "get" anything. They filed an application for an NDA. I can file an application for an NDA, too. For Cardiobacon.
THLD
This company should have died long ago after the BPH failure. I think this is the last nail in the coffin.
Commentary: Worth $4 Million -- and Unable to Retire
provided by Forbes
Okay, can someone explain this to me. $4 million invested wisely should make you *at least* 10% per year if invested conservatively and more than that with some strategy. Isn't $400k a year enough to retire? Take half (which is more than enough for a nice lifestyle, even in NYC, provided you don't have a mortgage to pay). Or have I missed something?
I got a call from a newly "rich" executive. Having worked 60-hour weeks for years and now ready to retire at 55, he sold his business for $4 million. He was ready to live out his dream life and live off that tidy nest egg. The problem is, to do so--on $4 million--he must cut his standard of living.
It's the plight of the "mMillionaire" -- the middle-class Millionaire.
Mansions and yachts are out. The mMillionaires who want to retire before age 65 or 72, find they must live in three- and four-bedroom homes and drive mid-priced four-door sedans and mini-vans.
They are your neighbors--millionaires who live middle-class lifestyles even though they may have millions in liquid assets.
More from Forbes.com:
• Slideshow: How to Retire a Millionaire
• Slideshow: Seven Retirement Saving Tips
• Slideshow: Seven Best (Unknown) Retirement Tax Havens
These mMillionaires have between $2 million and $10 million of investable assets, beyond their homes. Many have sold businesses or inherited money, yet few believe they can retire and continue living the high life.
The key question facing the mMillionaire is, "Can I continue to live the way I am living for the rest of my life?" The answer for most of these millionaires is "no."
Just a generation ago, a person with $2 million or more in liquid assets would have had enough for a secure retirement. But not today. Combine longer life expectancies and the rising costs of health care, food, transportation and property, and you have financial challenges ahead for the mMillionaire.
When Social Security was passed 72 years ago, life expectancy was less than 70. Now it's well above that and may continue to rise with advances in medical treatment. As a result, the mMillionaires in this high net worth class are finding they must scale back their lifestyles or delay retirement. That's something most of them, who are high-earners today, can't imagine.
For many of the executives and mMillionaires that I speak with everyday, this comes as a shock. Often their biggest obstacle is changing their own attitudes about what their wealth can afford them. Some are reluctant to embrace projections about their nest eggs' staying power. They believe that lower expenses in retirement will offset inflation and lost income.
Even with no mortgage or tuition payments, many mMillionaires underestimate the effects of inflation, especially on the cost of health care services for the aging.
We find that people don't always want to confront bad news. There's no question that more people are accumulating wealth at an unprecedented rate. They're living the good life, banking on retiring when they want to and continuing that quality through retirement. What they haven't counted on is that retirement can be a 40-year experience and that conditions can change drastically. In fact, in about 30 years, people will need more than $2 million to equal the purchasing power of $1 million today.
Many mMillionaires who are used to running businesses or managing others often want very specific answers on how to manage their middle-class millionaire status. Unfortunately, there's no formula for long-term financial security. Everyone's needs vary.
But, there are certain principles that can guide the mMillionaire's actions. If you are an mMillionaire, congratulations, but there are still a number of things you should keep in mind--ranging from managing your tax liabilities, to taking a really critical look at your investment portfolio (are you too heavily in tech stocks or consumer durables?), and of course guarding your estate, the nest egg you will leave behind.
Hi rfj1862,
I'm still investigating this but I think you're looking at the Energy Split Corp Preferred Shares (ES.PR.B). Energy Split Corp Capital Shares (ES) are different.
See this link:
http://www.scotiamanagedcompanies.com/mcapp/distributions.do?com=ESC
From what I can see "Split Shares" split the "investment returns on a portfolio of stocks into a lower risk dividend stream and a leveraged play on the price of the portfolio. Capital appreciation on the underlying portfolio is for the benefit of the capital shares, while the dividends received from the underlying portfolio are paid to the holders of the preferred shares."
Based on that statement, is the distribution from ES.TO simply return of capital? Or am I completely confused. To put it mildly, this equity is structured, um, uniquely.
Would love to know if anyone has comments on the potential problems with ES.
Have a nice day. And I like your new haircut!
Any Canadians out there?
Looking at ES.TO, which appears to pay 21% plus as a leveraged Canroy holder. Any thoughts? I'm having a hard time finding decent information on it, which doesn't bode well.
HTE has gone bonkers Canroy-style. Which isn't as exciting as biotech-style.
I still can't figure out why this trust is doing so well compared with peers.
Where’s that Seasonal Decline in Oil Prices? New Raymond James Report says ‘Forgetaboutit’
Posted: October 9, 2007
If you’re looking for crude oil prices to come down between now and the end of November just as they have each of the last three years, well, as Tony Soprano might say, you can “fuhgeddaboudit.”
There’ll be no price drop this year, according to a new report from the brokerage firm Raymond James & Associates, which has just raised its price estimate for the 2007 fourth quarter from $70 to $80 a barrel, which is approximately where prices are currently. “The global oil outlook looks as bullish as we have seen in many years,” Raymond James said in the report, which also made an initial 2009 price forecast of $85 a barrel – a figure which, if history is any guide, may well be raised as time goes on.
For investors, the significance of the new Raymond James report is that, not only should shares of major oil companies further rise as they generally do when the price of the commodity is rising, but shares of alternative energy companies may rise, too, as pressure mounts on government and business to improve energy efficiency and find alternatives to oil.
Compared with similar reports by other brokerage firms, the Raymond James energy-stat-of-the-week report for Oct. 1 looked farther into both the past and the future of oil, drawing a picture of a world about to enter an era even many oil traders have not seen.
For 40 years the world has had spare oil production capacity, or in industry jargon, an “oil bubble.” But the combination of a decade of sharply higher demand and disappointing non-OPEC supply growth has all but eliminated that bubble, according to Raymond James. Now, with rising prices still not causing lower demand, and with many of the world’s mature oilfields continuing to show precipitous declines that are offsetting new discoveries, supply constraints are likely to persist, with prices likely to rise until they finally serve to diminish demand.
Raymond James suggested that oil traders generally aren’t yet aware of the new era that oil has entered. In addition, traders continue to overestimate non-OPEC’s ability to raise production. Once traders see that they are wrong, this likely will cause prices to rise even higher, the report inferred.
Ken Heebner hates your office. And he thinks you’re probably getting fired.
http://www.dealbreaker.com/2007/09/ken_heebner_hates_your_office.php
Kenneth Heebner’s CGM Realty Fund is liquidating its positions in SL Green Realty Corp - Manhattan’s largest office landlord.
"You're seeing a retrenchment in the private-equity, hedge-fund and brokerage businesses, and there could be a lot of layoffs,' Heebner, 66 told Bloomberg in a recent interview. `That could have a devastating impact on high-end residential real estate in New York. Appetite for office space will also decline."
When people want to be polite, they talk about Heebner’s “independent streak” and “against the grain” investment strategies. When they want to be less polite they use phrases like “too gutsy to be practical,” as Morningstar once put it.
Heebner’s ”gutsy” bets don’t always work out. Focus, his biggest fund, returned just 3.5 percent in 1998, vs. 28.6 percent for Standard & Poor's 500. Realty lost 21.2 percent that year. He isn’t afraid to short blue chips such as Wal-Mart and Dell – companies he considers overvalued – an investment style some consider “quirky.” But just because you can’t win ‘em all, doesn’t mean you can’t sometimes win big.
Coming out of the late ‘90’s with underperforming, unbalanced funds, he mobilized back to life through the last seven years starting in 2000 when he made a killing short-selling telecom and tech stocks. Then again in 2001 when he bet on homebuilder stocks which were extremely profitable over the subsequent three years. Currently, CGM mutual funds consists of four funds - Capital Development, Focus, Realty and Mutual- leaving Heebner with over $6.6 billion under his management.
Just before the housing bubble began to burst, he feared the expansion of what he deemed “funny-money mortgages.” He aggressively lightened his homebuilder shares in 2005, turned around and poured the proceeds into energy stocks just before oil prices began to ascend. In the age of $80 a barrel oil and subprime sludge spilling over into even the better neighborhoods and all but wiping out homesales, quirky looks pretty smart.
Now Heebner’s dumping SL Green Realty Corp. Since they are the largest office space landlord in Manhattan, chances are, you work in an SL Green office space.
“Heebner, who had two-thirds of the real-estate fund in homebuilder stocks at the beginning of 2005, sold his entire stake by the end of that year. Homebuilder shares peaked in July 2005 and have since tumbled an average of 67 percent,” Bloomberg reports.
Relevant to HTE (which owns a refinery)
Goldman Sachs Oct 8
With $80 oil, 300 OSX, refiners have major upside potential
1. Refiners the biggest opportunity in energy sector. We believe investors should take advantage of investor obsession with traditional refining margin seasonality to add to positions over the next 4-6 weeks.
We see the refiners as overwhelmingly having the most favorable risk/reward among energy sub-sectors and reiterate our Attractive coverage view. Our favorite US refiners are Buy-rated Valero Energy and Sunoco, though we expect all four of our covered companies including Neutral-rated Frontier Oil and Tesoro to perform well.
2. $80 oil and 300 OSX are not consistent with depressed refining valuations. In our view, oil at $80/bbl and the OSX at 300 are not consistent with depressed refining sector share prices. Given our bullish commodity view for 4Q 2007 and 2008, we think the gap will close via a sharp rally in the refiners.
While trading is likely to remain choppy over the next 4-6 weeks during the remainder of the “shoulder months”, we do not believe the refiners will fall through mid-August lows in the absence of a meaningful sell-off in the S&P 500.
In terms of upside, we believe an $80/bbl oil price—which is our base-case forecast for 2008—is consistent with $14/bbl Gulf Coast 3:2:1 refining margins and 42% upside for refining equities on average to our 12-month target prices (based on asset value, P/E and cash flow valuation analyses; key risk is sustained lower commodity prices).
3. VLO “convergence trade” points to trading upside. We find that Valero Energy’s shares (adjusted for the level of the S&P 500) are strongly correlated with moves in the 2-year WTI strip and 1-year Gulf Coast 3:2:1 strip. At the moment, Valero’s share price looks very undervalued based on the current WTI 2-year strip and 1-year Gulf Coast 3:2:1 strip. Given the “convergence trade” nature of the analysis, the question for investors is whether the strip prices fall or Valero’s share price (relative to S&P 500) rises.
The current 2-year WTI strip is $76.50/bbl and the 1-year Gulf Coast 3:2:1 strip is $12.25/bbl, both of which are below our respective 2008 forecasts of $80/bbl and $14/bbl, respectively. As such, we believe Valero’s share price will rally at a minimum to levels consistent with the current commodity strip prices. However, with both crude oil and refining margins expected to rally further over the next year, we believe additional absolute upside exists in Valero shares.
HTE
Can someone explain to me why HTE is doing so well relative to other Canroys (which are flat in my portfolio)?
It would seem to me that with declining oil prices and shrinking crack spreads, HTE should be performing less well. Of course it is undervalued, but so are all the other Canroys.
Please no snide comments about crack spreads.
"Medihoney" reminds me of "Cardioaspirin," the term Bayer is using to market...aspirin.
I wish someone would come up with Cardiobacon.
NCT May $17.50 puts going for $3.30.
I'm not biting, but some of you might be interested.
TMA
Anyone have any thoughts about TMA? Yields 20%. I'm a little torn because they are a single-family residential mortgage lender (which is bad) but they lend to top income bracket sorts, which should be significantly lower risk than lending to those of us at the bottom of the barrel.
Also some analyst (can't remember who--desperately searching for the link) noted that TMA is worth about $16 if sold. I need to do my own DD, but it's a promising start.
I just looked at the Kim Snider website as well. Good stuff, a little too general for me though.
Hey,
I think you're on the wrong board
My screen is simple. I just look at the top 30 or 40 yielders, and investigate each one in turn. I also try to buy in baskets to avoid company-specific exposure. My baskets currently include Canroys, BDCs, and REITs. I don't own any shippers right now as their prices are a bit inflated.
If you have specific suggestions for stock screeners or other resources, feel free to supply the links and I'll add them to the I-Box.
A friend just told me that he couldn't register with a Yahoo address. Has there been a change in policy or should I take away his crack pipe (again).
Rate Cut Not Needed for Year-End Rally
Saturday October 6, 6:42 am ET
By Joe Bel Bruno, AP Business Writer
I consider most all AP Business writing near-spam. Content-free. Nevertheless, for what it's worth, I bring you:
Interest Rate Cut Might Not Be Needed to Fuel a Fourth-Quarter Rally on Wall Street
NEW YORK (AP) -- Although the prospects for a late October interest rate cut have dimmed, the chances for a yearend stock rally still seem quite good.
Investors have been feeling more confident since the Federal Reserve cut rates a half percentage point on Sept. 18, and were looking for a repeat at the Fed's Oct. 30-31 meeting to keep stocks driving higher. But while a strong jobs report from the Labor Department lessened the likelihood of a rate cut this month, there's growing sentiment that one might not be needed for Wall Street to have its traditional fourth-quarter rally.
Market watchers believe upcoming reports might also point to a healthy economy, and might even help offset what is expected to be a sluggish earnings reporting season for U.S. companies.
"The Fed and the markets will be watching all the incoming data very closely, but it really seems unlikely we'll get enough negative data that will force them to once again lower rates," said Michael Sheldon, chief market strategist at Spencer Clarke LLC. "It will take an awful lot to bring the Fed off the sidelines, and we're heading into a historically strong part of the year."
Indeed, the Dow Jones industrial average has rallied during the final quarter for the past nine years straight. The Standard & Poor's 500 index has had a fourth-quarter sprint in 13 of the past 15 years.
The current optimism is a turnaround from Wall Street's mood of just over a month ago, when any rally seemed in jeopardy amid a harrowing tightening of credit, continuing erosion in the housing sector, and escalating energy prices. The Fed's half-point rate cut helped restore investors' faith in stocks and the economy overall.
Sheldon and other analysts say they aren't all that concerned about what the Fed does later this month. That's already been reflected in the futures that track the federal funds rate, which dropped from almost unanimous expectation for a cut to about a 50 percent chance.
"The market is really in a sweet spot for a number of reasons," said Todd Salamone, director of trading at Schaeffer's Investment Research in Cincinnati. "You felt a rate cut coming if there was bad data, and more confidence in the economy if there was good data. You really couldn't lose, and that's where we want to stay."
Much of the data out in the coming weeks will only partly reflect the effects of the Sept. 18 rate cut. Because of this, investors might have already discounted any bad news that might come out, Salamone said.
Minutes from the Federal Reserve's last meeting will be released Tuesday and they will be closely monitored to gauge the Fed's inclination toward another cut. However, analysts believe the real key to sending stocks higher will be third-quarter earnings.
Strong results, or even those that simply keep pace with Wall Street's already lowered expectations, might keep the fourth-quarter rally going. If third-quarter results become choppy, and if companies in their fourth-quarter forecasts hint that the worst might not be over, than fears of recession could again creep back into the market.
Standard & Poor's said blue chip companies in the third quarter will report the lowest growth rate in five years. Members of the S&P 500 were originally expected to in the aggregate report a 2.4 percent gain for the quarter, but last week, the rating agency said it now expects a slight loss overall.
That forecast might be expected to dash hopes for a strong finish to the year. However, market watchers believe it might have the opposite effect -- the fourth quarter historically is when companies take charges to balance out their books for the year, and most investors will be focused instead on forward-looking statements.
And, in an era where beating earnings expectations will send shares of those companies rallying, lowering the bar makes that easier to achieve.
"The most important point is that you have a ton of sideline money out there," Salamone said. "And, being able to jump through lower expectations might be enough to bring them back in
In case you missed it:
CAN$1 = US$1.019
>Anyone else do this or am I the lone ranger on this? If others do this, how successful are you and care to share any tips we can use?<
This isn't my bag, but you might check out Carla Pasternak's newsletter, which lists dividend capture dates for a bunch of high-yield stocks, including some I'd never think of. Plus it's cheap--the time savings for you should much more than counterbalance the cost of the newsletter.
Thanks to Abreis for mentioning this newsletter first.
KF is definitely not for me...just mentioned because I thought Jim might be interested.
You know, Abreis (another poster who does not post often) mentioned the Korea Fund, which has an end-of-year distribution of something like $11. Not sure if it is ex-distribution yet. Let me know what you learn if you check it out.
This might sound stupid, but I wonder if there's an option strategy where you could capture the dividend and make money on puts when it goes ex-dividend. This is just off the top of my head--didn't even check to see if KF has options.
PS: I really appreciate the posts--more ideas please!
Update: here's the original post from Abreis
OT RE: ADVDX
The fund is a top recommendation of Carla Pasternack's High Yield Investment Newsletter. The Manager of this Alpine Fund is very knowledgeable on how to get the most out of dividend payouts and ex dates. It usually tracks the S&P as many of its holding are top companies (Merrill Lynch being one). I own it and like the results so far.
Note. You might want to look at symbol KF a Korean fund that is paying out $14.55 per share (capital gains disbursement) probably in November. It also has a 9% dividend and has an excellent track record. This is not a misprint!
Abreis
AFN
After much deliberation, I decided to take on a little more risk and buy some AFN. The dividend (which is an astonishing 24%) appears secure. I'd suspect AFN will go up to a point where the dividend is more in line with other high-yielding stocks.
Can't be more risky than a biotech, eh?
New resource: Downloadable spreadsheets of all dividend stocks, sorted by dividend.
http://wallstreetnewsnetwork.com/#Dow%20Stocks
I'm going to stop updating the list of high-yield stocks as this serves much the same purpose.